Understanding the Condition
Duchenne muscular dystrophy, often called DMD, is a genetic muscle disorder that mostly affects boys. It is caused by changes in the gene responsible for producing dystrophin, a protein that helps keep muscles strong and stable.
When the body doesn’t make enough functional dystrophin, muscles become more fragile over time. This can lead to progressive muscle weakness, difficulty walking, reduced endurance, and eventually challenges involving breathing and heart function.
Current treatments can help manage symptoms and slow progression, but researchers continue to explore new approaches that may support muscle health, reduce inflammation, and improve long-term care options.
Why Researchers Looked at Wharton’s Jelly MSCs
This study focused on a cell therapy called EN001, which is made from Wharton’s jelly-derived mesenchymal stem cells. Wharton’s jelly is the soft tissue found inside the umbilical cord.
Mesenchymal stem cells, or MSCs, are being studied in regenerative medicine because they release helpful signals that may influence inflammation, tissue repair, immune activity, and cell communication.
For muscle-related conditions like DMD, researchers are interested in whether MSC-based therapy may help create a more supportive environment for muscle cells. The main goal isn’t really to claim that MSCs replace missing dystrophin or cure DMD, but instead the focus is on whether these cells may be safe and whether they could support future treatment strategies.
How the Study Was Set Up
This was an open-label, dose-escalation phase 1 clinical trial. Simply put, it was an early human study designed mainly to evaluate safety and determine whether the treatment was well tolerated.
The study included six pediatric patients with DMD. The participants were divided into two groups:
- A low-dose group receiving 5.0 × 10⁵ cells per kilogram
- A high-dose group receiving 2.5 × 10⁶ cells per kilogram
All patients were monitored for 12 weeks after receiving EN001. Researchers watched closely for any serious side effects, dose-limiting toxicity, or other safety concerns.
They also explored early signs of potential benefit by looking at blood markers and functional tests. These included creatine kinase levels, breathing tests, muscle strength testing, the North Star Ambulatory Assessment, and the six-minute walk test.
What the Researchers Found
The main finding was encouraging from a safety perspective. No participants experienced serious adverse events related to EN001 during the 12-week follow-up period.
Some mild side effects were reported, including injection-related redness, swelling, headache, and changes in smell. However, the study didn’t find dose-limiting toxicity. This means the tested doses did not cause side effects severe enough to stop dose evaluation.
The researchers also looked at functional outcomes after 12 weeks. These tests did not show significant changes compared with baseline. Since this was a small phase 1 study with only six participants, the main focus was safety rather than proving effectiveness.
The study also measured creatine kinase, or CK, which is a blood marker often elevated when muscle damage is present. CK levels were reduced compared with baseline at most visits after treatment, although the changes were not statistically significant.
What This Means in Simple Terms
This study does not prove that Wharton’s jelly-derived MSCs improve DMD. However, it does provide an important early step: showing that EN001 was generally well tolerated in this small group of pediatric patients.
That matters because before researchers can study whether a therapy may be effective, they first need to understand whether it appears safe enough to continue testing.
For DMD research, safety is especially important because patients are often children, and the condition requires long-term management. Any new treatment approach must be carefully studied before it can be considered for broader use.
Why This Study Matters for Regenerative Medicine
This study adds to the growing field of regenerative medicine research focused on cell signaling, inflammation balance, and tissue support.
MSCs are often described as “messenger cells” because they release signals that may influence how surrounding cells behave. In muscle conditions, these signals may be studied for their potential to support repair-related pathways, calm harmful inflammation, and improve the tissue environment.
Wharton’s jelly-derived MSCs are especially interesting because they come from umbilical cord tissue, a young source of cells that researchers continue to study for immune-regulating and repair-supportive properties.
The Bigger Picture
Because this was an early phase 1 trial, there are important limitations. The study included only six patients, did not include a placebo group, and followed patients for a relatively short 12-week period.
The researchers noted that larger future studies are needed. These studies may include repeated dosing, longer follow-up, and randomized controlled trial designs to better understand whether EN001 may provide meaningful benefits for muscle function, endurance, breathing, or other DMD-related outcomes.
Still, this early study provides a foundation for future research by showing that the treatment was tolerated without serious treatment-related safety concerns in the group studied.
Main Takeaway
This phase 1 clinical study explored Wharton’s jelly-derived MSC therapy in pediatric patients with Duchenne muscular dystrophy. The treatment was generally well tolerated, with no serious adverse events related to EN001 and no dose-limiting toxicity during the 12-week follow-up period.
While the study did not show significant functional improvements, it was mainly designed to evaluate early safety. The findings support continued research into Wharton’s jelly-derived MSCs as a potential regenerative medicine approach for muscle health, inflammation balance, and future DMD treatment strategies.
Source
Lee J, Park SE, Kim M, Kim H, Kwon JY, Jeon HB, Chang JW, Lee J. Safety and Tolerability of Wharton’s Jelly-Derived Mesenchymal Stem Cells for Patients With Duchenne Muscular Dystrophy: A Phase 1 Clinical Study. Journal of Clinical Neurology. 2025 Jan;21(1):40–52. doi: 10.3988/jcn.2024.0299. PMID: 39778566; PMCID: PMC11711273. https://pmc.ncbi.nlm.nih.gov/articles/PMC11711273/
Related Treatment Pages